Recent Updates
Recently added Catalysts

rehabilitation

Phase 2

Quality of Life | Unknown | Other |Novo Nordisk A/S|Last Updated: Dec 4, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment196
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00569478The Effect of Rehabilitation for Patients Living With an Implantable Cardioverter DefibrillatorPHASE2 COMPLETED 196Oct 1, 2007Oct 1, 2011Dec 4, 20121 Denmark
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Quality of life
3 -6-12 month
Physical capability
3-6-12 month
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeSUPPORTIVE_CARE
Treatment Arms
ArmTypeDescription
1ACTIVE_COMPARATORrehabilitation
2NO_INTERVENTIONcontrols
Interventions
NameTypeDescription
rehabilitationOTHERNursing consultations and physical training
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * In-patients at Copenhagen University Hospital who just received an ICD for the first time. Exclusion Criteria: * Patients who: * do not understand the instructions, * are under 18 years old, * are diagnosed with a mental disease, * suffer from a competing disease, ...

Countries:Denmark
Unlock Eligibility Criteria